Longevity Medicine and Weight-Loss Drugs Merge
There’s an interesting intersection happening between two popular health trends: longevity medicine and weight-loss drugs.
For a while now, biohackers and aging researchers have been speculating that GLP-1 medications, like Ozempic and Zepbound, could potentially extend lifespan. Some online pharmacies even offer compounded versions of these drugs, claiming they can boost health span. However, there hasn’t been much academic scrutiny on this idea—until recently.
A recent study marked one of the first attempts to explore this notion. It focused on participants with HIV and lipohypertrophy, revealing that an eight-month regimen of semaglutide (the active component in Ozempic) seemed to slow down biological aging based on blood tests measuring age-related markers. Since individuals with HIV typically experience accelerated aging due to the virus, they represent a valuable demographic for such research, according to Michael Corley, an associate professor at the University of California, San Diego.
The study was preliminary but raised an essential question: was there any evidence to support the hype surrounding these medications? Dr. Corley noted that this research could serve as a starting point.
The Hype Behind GLP-1s
So why is there such excitement? Evidence suggests that GLP-1 medications improve metabolic health by aiding in insulin regulation and weight loss. Numerous studies have also indicated that these drugs positively impact cardiovascular, liver, and kidney health.
Given that these drugs can mitigate conditions like diabetes and heart disease—major contributors to mortality—it’s reasonable to consider them as potential longevity treatments. Dr. Nicolas Musi, director of the Diabetes and Aging Center at Cedars-Sinai, noted that GLP-1 agonists seem to lower the incidence of age-related diseases, which could imply they might also help prolong life.
Experts are intrigued by how these drugs interact with cellular health. Since metabolic health is closely related to aging, interventions affecting metabolic pathways may also influence the aging process.
Dr. Musi highlighted that many of the pathways modified by diabetes medications are crucial for controlling aging and longevity. Some alternative diabetes medications, such as metformin and SGLT2 inhibitors, are also currently under investigation for their potential longevity benefits, though the evidence remains mixed.
Impacts on Inflammation and Cellular Health
GLP-1s also appear to affect fundamental cellular changes associated with aging, particularly inflammation. Dr. Thomas Blackwell, a professor at the University of Texas, explained that these drugs exhibit significant anti-inflammatory effects, which could combat one of the factors accelerating aging.
Despite the promising aspects, a significant caveat exists: there’s currently very little information on whether GLP-1 drugs might benefit those with a healthy metabolism.
Interestingly, there are even gaps in knowledge regarding their efficacy in extending the lifespan of healthy rodents. Dr. Richard Miller from the University of Michigan pointed out logistical challenges. The GLP-1 medications we have may not function similarly in mice, or they might require delivery methods—like injections—that aren’t practical for long-term studies in these animals.
Concerns also arise regarding potential adverse health effects of GLP-1s, particularly in older adults. Notably, these drugs can lead to muscle loss, which poses a risk for frailty in aging populations. Additionally, rapid weight loss associated with GLP-1 use might decrease bone density, heightening osteoporosis risk.
Currently, several clinical trials are examining GLP-1s in relation to various aging biomarkers, such as inflammation levels and biological aging markers, as well as functional capabilities like strength and walking speed. Nevertheless, some studies may not involve healthy older adults, focusing instead on participants who qualify for weight-loss prescriptions—criteria that reflect a substantial portion of the American population, according to Dr. Blackwell.
Current Recommendations
At this stage, experts generally advise against using these medications off-label for longevity purposes. Dr. Musi emphasized the lack of data justifying this approach for otherwise healthy individuals.
Interestingly, Dr. Blackwell, while advocating caution, is personally using tirzepatide (Zepbound) in hopes of slowing his own aging process. He admitted uncertainty regarding the appropriateness of this choice, stating he does not recommend it for his patients.
“This is my own personal decision,” he noted, highlighting the tension between personal agency and professional recommendations.
